Opportunity to License/Acquire CMX-2043 For Treatment of Traumatic Brain Injury
Ischemix is a privately-held US company developing a novel cytoprotective drug, CMX-2043, for the treatment of acute moderate-to-severe...
top of page
Sage Group News
bottom of page